Resistance to anti-angiogenic agents: A brief review of mechanisms and consequences

Translational Lung Cancer Research

Volumn 2, Issue 4, 2013, Pages 304-307

  Edelman, Martin J ^a   Mao, Li ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN;

ADAPTATION; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CONVERGENT EVOLUTION; DRUG RESISTANCE; ECOLOGICAL NICHE; ENDOTHELIUM CELL; HUMAN; MEDICAL LITERATURE; SHORT SURVEY; SURVIVAL ANALYSIS; VASCULAR SMOOTH MUSCLE CELL;

EID: 84952637978     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2013.01.02     Document Type: Short Survey

References (26)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008;8:592-603.
4. Merlo LM, Pepper JW, Reid BJ, et al. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-35.
5. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012;12:487-93.
6. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13.
7. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008;8:592-603.
8. Jonasch E, Futreal PA, Davis IJ, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012;10:859-80.
9. Ebos JM, Lee CR, Christensen JG, et al. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007;104:17069-74.
10. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
11. Franco M, Roswall P, Cortez E, et al. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011;118:2906-17.
12. Nisancioglu MH, Betsholtz C, Genové G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res 2010;70:5109-15.
13. Xian X, Håkansson J, Ståhlberg A, et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006;116:642-51.
14. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
15. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997;151:1417-23.
16. Chumsri S, Phatak P, Edelman MJ, et al. Cancer stem cells and individualized therapy. Cancer Genomics Proteomics 2007;4:165-74.
17. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72.
18. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-81.
19. Kirschmann DA, Seftor EA, Hardy KM, et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012;18:2726-32.
20. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
21. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
22. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9.
23. Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2011;6:e22681.
24. Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24:20-30.
25. Vokes EE, Salgia R, Karrison TG. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol 2013;24:6-9.
26. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.